The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Determining the optimal frontline treatment of AML
Curtis Lachowiez, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes frontline treatment strategies for patients with acute myeloid leukemia (AML). Dr Lachowiez emphasizes the importance of disease-related and patient-related factors when determining to optimal frontline strategy for an individual. Firstly, a patient’s age and fitness must be considered, to determine their eligibility for standard upfront intensive chemotherapy. Patients thought to be unable to tolerate this regimen are instead treated with targeted agents as a more tolerable way to achieve remission. Additionally, a patient’s risk categorization plays an important role in deciding what to do when they achieve remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
